prIME Rounds: Update on Immunotherapy for Head and Neck Cancer
This CME-certified prIME Rounds webcast centers on immunotherapy in head and neck cancer, focusing on the use of checkpoint inhibitors in squamous cell carcinoma of the head and neck.
- Why targeting immune system in SCCHN
- Use of immune checkpoint inhibitors in SCCHN in practice
- Next steps in SCCHN
Ezra Cohen, MDUniversity of California at San Diego
San Diego, California, United States
This educational activity is designed for medical oncologists, radiation oncologists, head and neck surgeons, and other healthcare professionals involved in the treatment of patients with head and neck cancer.
After completion of this educational activity, participants should be able to:
- Identify rationale and current indications for use of immune checkpoint inhibitors in recurrent and metastatic HNSCC
- Explain unique patterns of response to immuno-oncology agents and management of immune-related adverse events
- Assess the potential impact of biomarkers such as human papillomavirus (HPV) status, programmed death-ligand 1 (PD-L1), mutational load, and expression profiling on response to immunotherapy
- Incorporate current and emerging immuno-oncology strategies to multidisciplinary care of head and neck cancer
This activity is provided by prIME Oncology.
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
prIME Oncology designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.CME and Disclosure Information
This educational activity is supported by a grant from Bristol-Myers Squibb.
December 22, 2017
December 22, 2018